LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
Oct 15, 2018more +
LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient
Oct 2, 2018more +
Christensenella: the cornerstone of the gut microbiota?
Jul 6, 2018more +
LNC Therapeutics appoints new CEO, Dr. Georges Rawadi, and accelerates development in microbiome...
Apr 17, 2018more +
LNC Therapeutics raises € 6,5 million and reinforces its R&D in the Microbiota field
Sep 27, 2017more +